Switch theme
Sign up to access all valuation multiples
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
1982
220
LTM Revenue $48.2M
LTM EBITDA -$11.2M
$66.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Apyx Medical has a last 12-month revenue (LTM) of $48.2M and a last 12-month EBITDA of -$11.2M.
In the most recent fiscal year, Apyx Medical achieved revenue of $48.1M and an EBITDA of -$16.8M.
Apyx Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Apyx Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $48.2M | XXX | $48.1M | XXX | XXX | XXX |
| Gross Profit | $29.2M | XXX | $29.4M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | -$11.2M | XXX | -$16.8M | XXX | XXX | XXX |
| EBITDA Margin | -23% | XXX | -35% | XXX | XXX | XXX |
| EBIT | -$15.4M | XXX | -$18.8M | XXX | XXX | XXX |
| EBIT Margin | -32% | XXX | -39% | XXX | XXX | XXX |
| Net Profit | -$19.9M | XXX | -$23.5M | XXX | XXX | XXX |
| Net Margin | -41% | XXX | -49% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Apyx Medical's stock price is $2.
Apyx Medical has current market cap of $59.0M, and EV of $66.9M.
See Apyx Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $66.9M | $59.0M | XXX | XXX | XXX | XXX | $-0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Apyx Medical has market cap of $59.0M and EV of $66.9M.
Apyx Medical's trades at 1.4x EV/Revenue multiple, and -4.0x EV/EBITDA.
Equity research analysts estimate Apyx Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Apyx Medical has a P/E ratio of -3.0x.
See valuation multiples for Apyx Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $59.0M | XXX | $59.0M | XXX | XXX | XXX |
| EV (current) | $66.9M | XXX | $66.9M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -6.0x | XXX | -4.0x | XXX | XXX | XXX |
| EV/EBIT | -4.4x | XXX | -3.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -2.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialApyx Medical's last 12 month revenue growth is 3%
Apyx Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Apyx Medical's rule of 40 is -32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Apyx Medical's rule of X is -16% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Apyx Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | -23% | XXX | -35% | XXX | XXX | XXX |
| EBITDA Growth | -32% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -32% | XXX | -32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -16% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 100% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apyx Medical acquired XXX companies to date.
Last acquisition by Apyx Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Apyx Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Apyx Medical founded? | Apyx Medical was founded in 1982. |
| Where is Apyx Medical headquartered? | Apyx Medical is headquartered in United States of America. |
| How many employees does Apyx Medical have? | As of today, Apyx Medical has 220 employees. |
| Who is the CEO of Apyx Medical? | Apyx Medical's CEO is Mr. Charles D. Goodwin, II. |
| Is Apyx Medical publicy listed? | Yes, Apyx Medical is a public company listed on NAS. |
| What is the stock symbol of Apyx Medical? | Apyx Medical trades under APYX ticker. |
| When did Apyx Medical go public? | Apyx Medical went public in 1994. |
| Who are competitors of Apyx Medical? | Similar companies to Apyx Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Apyx Medical? | Apyx Medical's current market cap is $59.0M |
| What is the current revenue of Apyx Medical? | Apyx Medical's last 12 months revenue is $48.2M. |
| What is the current revenue growth of Apyx Medical? | Apyx Medical revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Apyx Medical? | Current revenue multiple of Apyx Medical is 1.4x. |
| Is Apyx Medical profitable? | Yes, Apyx Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Apyx Medical? | Apyx Medical's last 12 months EBITDA is -$11.2M. |
| What is Apyx Medical's EBITDA margin? | Apyx Medical's last 12 months EBITDA margin is -23%. |
| What is the current EV/EBITDA multiple of Apyx Medical? | Current EBITDA multiple of Apyx Medical is -6.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
